Alfresa Holdings Corp

Alfresa Holdings Corp maintains a strong liquidity position, with cash and equivalents amounting to ¥177.09 billion, representing 12.3% of total assets. The company's liquidity ratio of 1.22 indicates a healthy short-term financial position, with current assets comfortably covering current liabilities. The debt-to-equity ratio of 0.07 suggests a conservative capital structure, with long-term debt at ¥35.55 billion representing only 7.4% of total equity. Profitability metrics show a return on equity (ROE) of 5.69% and a return on assets (ROA) of 1.9%, both below the industry median for medical equipment and services. The company's operating margin of 10.4% (¥30.83 billion operating income on ¥296.11 billion revenue) is in line with industry norms, but its net margin of 0.93% (¥2.74 billion net income) is significantly lower than the sector average, indicating potential inefficiencies in cost management or tax optimization. The company's revenue is concentrated in its core healthcare services and equipment segment, with no material geographic diversification disclosed in the available data. This concentration increases exposure to regional healthcare policy changes and demand fluctuations. No material revenue is attributed to international operations, suggesting a primarily domestic business model. Looking ahead, Alfresa Holdings Corp is projected to see modest revenue growth, with analysts forecasting a mean price target of ¥2,475.00, representing a 9.4% upside from the current market price of ¥2,261.50. The company's free cash flow of ¥9.68 billion and operating cash flow of ¥10.85 billion support its ability to fund operations and potentially return capital to shareholders. However, capital expenditures of ¥20.13 billion suggest ongoing investment in infrastructure and expansion. The company's risk profile is characterized by low liquidity and dilution risks, with no immediate filing-based flags detected. The low dilution risk is supported by the absence of recent share issuance activity and the alignment of basic and diluted shares outstanding. The conservative debt structure and strong cash position further mitigate financial risk. Recent investor relations data shows a neutral analyst sentiment, with three "hold" recommendations and no "buy" or "strong buy" ratings. The mean recommendation score of 3.00 suggests a cautious outlook, with price targets ranging from ¥2,400 to ¥2,550. This indicates a consensus for moderate upside potential but limited enthusiasm for aggressive growth.